Mechanistic note
AKR1B10 has often been discussed as a disease-associated marker in steatohepatitis and liver injury. However, an increasingly important question is whether AKR1B10 is only a marker of disease state, or whether it can actively contribute to the persistence of a lipogenic hepatic state.
A 2024 study by Lin et al. adds a particularly relevant functional layer to this question. The authors investigated nicotinate-curcumin in experimental NASH models and focused on the AKR1B10/ACCα pathway. In a high-fat/high-fructose rat model and in Ox-LDL/high-glucose-stressed HepG2 cells, they report increased AKR1B10 and ACCα together with changes in Malonyl-CoA, free fatty acids and triglycerides. Treatment with nicotinate-curcumin reduced AKR1B10/ACCα signaling and was associated with lower Malonyl-CoA, FFA and TG levels.
This supports the view that AKR1B10 is more than a passive NASH-associated readout. ACCα catalyzes the formation of Malonyl-CoA, a central building block for fatty acid synthesis. If AKR1B10 helps to maintain ACCα-dependent lipid synthesis, it may participate in stabilizing the metabolic output of the diseased hepatocyte.
This connects back to my earlier PXR/steatosis work in human hepatic cells. In 2015, we reported that ligand-dependent PXR activation and reduced PXR signaling can both promote steatosis, but through distinct mechanisms. PXR activation induced SREBP1a and lipogenic SREBP1 target genes, whereas PXR knockdown increased AKR1B10 and an ACC-dependent branch of de novo lipogenesis. In histologically classified human NASH liver samples, PXR protein was reduced, while AKR1B10, SREBP1a and lipogenic target genes were increased.
The work by Lin et al. therefore does not stand isolated. It strengthens a mechanistic line in which AKR1B10 links stress-associated hepatic remodeling to ACCα, Malonyl-CoA, FFA and triglyceride synthesis.
This is also relevant for the Detoxification State Fixation (DSF) framework. In the DSF model, AKR1B10 is proposed as one of the molecular anchors that may help stabilize an originally adaptive detoxification-lipogenic hepatic state beyond its normal resolution window. The important point is not that AKR1B10 alone “causes” NASH. Rather, AKR1B10 may help maintain one part of a self-reinforcing state: persistent lipogenic output under disease-shaped stress conditions.
From this perspective, AKR1B10 becomes more than a biomarker. It becomes a candidate state-stabilizing node.
This does not prove DSF as a whole. But it provides independent functional support for one of its proposed molecular anchors: AKR1B10 as a lipogenic control node connecting detoxification-associated stress biology with persistent hepatic lipid synthesis.
Related framework:
Detoxification State Fixation (DSF)
https://srebp1a.com/state-fixation/
References
Lin, X.-L. et al. Nicotinate-curcumin improves NASH by inhibiting the AKR1B10/ACCα-mediated triglyceride synthesis. Lipids in Health and Disease 23, 201 (2024). https://doi.org/10.1186/s12944-024-02162-5
Bitter, A. et al. Pregnane X receptor activation and silencing promote steatosis of human hepatic cells by distinct lipogenic mechanisms. Archives of Toxicology 89, 2089-2103 (2015). https://doi.org/10.1007/s00204-014-1348-x